Irhythm Technologies Inc. logo

Irhythm Technologies Inc. (IRTC)

Market Open
11 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
135. 94
+1.23
+0.91%
$
4.55B Market Cap
- P/E Ratio
0% Div Yield
562,300 Volume
-3.38 Eps
$ 134.71
Previous Close
Day Range
133.18 137.39
Year Range
55.92 157.13
Want to track IRTC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 16 days

Summary

IRTC trading today higher at $135.94, an increase of 0.91% from yesterday's close, completing a monthly decrease of -3.05% or $4.27. Over the past 12 months, IRTC stock gained 50.18%.
IRTC is not paying dividends to its shareholders.
The last earnings report, released on Apr 30, 2025, exceeded the consensus estimates by 0.69%. On average, the company has surpassed earnings expectations by 0.52%, based on the last three reports. The next scheduled earnings report is due on Jul 30, 2025.
The stock of the company had never split.
The company's stock is traded on 7 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).

IRTC Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
iRhythm Technologies, Inc. (IRTC) Q1 2025 Earnings Call Transcript

iRhythm Technologies, Inc. (IRTC) Q1 2025 Earnings Call Transcript

iRhythm Technologies, Inc. (NASDAQ:IRTC ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Stephanie Zhadkevich - Director, IR Quentin Blackford - President & CEO Daniel Wilson - CFO Conference Call Participants Allen Gong - JPMorgan Kallum Titchmarsh - Morgan Stanley Macauley Kilbane - William Blair Nathan Treybeck - Wells Fargo David Rescott - Baird David Saxon - Needham & Company Suraj Kalia - Oppenheimer Jon Young - Canaccord Genuity Sam Eiber - BTIG Richard Newitter - Truist Operator Good afternoon. Thank you for attending the iRhythm Technologies, Inc. First Quarter 2025 Earnings Conference Call.

Seekingalpha | 2 months ago
IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates

IRhythm Technologies (IRTC) Reports Q1 Loss, Tops Revenue Estimates

IRhythm Technologies (IRTC) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to loss of $1.47 per share a year ago.

Zacks | 2 months ago
iRhythm Technologies (IRTC) Upgraded to Buy: Here's What You Should Know

iRhythm Technologies (IRTC) Upgraded to Buy: Here's What You Should Know

iRhythm Technologies (IRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 3 months ago

Irhythm Technologies Inc. Dividends

IRTC is not paying dividends to its shareholders.

Irhythm Technologies Inc. Earnings

7 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
20 Feb 2025 Date
-
Cons. EPS
0.01
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS
IRTC is not paying dividends to its shareholders.
7 Aug 2025 (In 3 weeks) Date
-
Cons. EPS
-
EPS
30 Jul 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
30 Apr 2025 Date
-
Cons. EPS
-
EPS
20 Feb 2025 Date
-
Cons. EPS
0.01
EPS
31 Oct 2024 Date
-
Cons. EPS
-
EPS

Irhythm Technologies Inc. (IRTC) FAQ

What is the stock price today?

The current price is $135.94.

On which exchange is it traded?

Irhythm Technologies Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is IRTC.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 4.55B.

When is the next earnings date?

The next earnings report will release on Jul 30, 2025.

Has Irhythm Technologies Inc. ever had a stock split?

No, there has never been a stock split.

Irhythm Technologies Inc. Profile

Medical - Devices Industry
Healthcare Sector
Quentin S. Blackford CEO
NASDAQ (NGS) Exchange
450056106 Cusip
US Country
2,000 Employees
- Last Dividend
- Last Split
20 Oct 2016 IPO Date

Overview

iRhythm Technologies, Inc. is a pioneering digital healthcare organization primarily focused on the design, development, and deployment of innovative device-based solutions aimed at the ambulatory cardiac monitoring sector within the United States. Leveraging advanced technology, the company's mission revolves around facilitating the diagnosis of arrhythmias—irregular heartbeats that can lead to serious health issues. The essence of iRhythm's offering is encapsulated in its commitment to enhancing cardiac care through digital innovation, where it brings a unique blend of clinical expertise and technological prowess. Established in 2006 and based in San Francisco, California, the company has established itself as a key player in the realm of cardiac healthcare by offering groundbreaking services that significantly improve patient outcomes. Additionally, iRhythm Technologies maintains a collaborative development agreement with Verily Life Sciences LLC and Verity Ireland Limited, focusing on the creation of cutting-edge atrial fibrillation screening, detection, and monitoring products, thereby broadening its impact on patients' lives.

Products and Services

  • Zio services
  • iRhythm provides the Zio services as an innovative ambulatory monitoring solution that caters to the needs of patients requiring long-term, short-term continuous monitoring, and mobile cardiac telemetry monitoring services. The essence of Zio services lies in their ability to offer comprehensive cardiac monitoring, thereby facilitating timely and accurate diagnosis of arrhythmias. Through Zio services, patients benefit from a sophisticated monitoring approach that combines convenience with clinical efficacy.

  • Zio Monitor System
  • At the heart of iRhythm's product lineup is the Zio Monitor System, a state-of-the-art remote electrocardiogram (ECG) monitoring system that includes a wearable patch ECG monitor. Capable of recording the electrical signals from the heart continuously for up to 14 days, this system exemplifies the seamless integration of technology and healthcare. In conjunction with the Zio ECG Utilization Software System, it supports the comprehensive capture and analysis of ECG data, including the identification of specific arrhythmia events. The system is prescription-only, emphasizing its role as a sophisticated diagnostic tool in the hands of healthcare professionals.

  • Zio XT System
  • The Zio XT System represents the previous generation of the Zio Monitor System, maintaining its role as a vital tool for remote ECG monitoring. Also designed to be worn for up to 14 days, the Zio XT patch continuously records the heart's electrical activity, offering a blend of reliability and convenience for patients. As a prescription-only system, it underscores iRhythm's commitment to delivering professional-grade cardiac monitoring solutions.

  • Zio AT System
  • Last but not least, the Zio AT System extends the capabilities of remote ECG monitoring with its innovative design. Similar to its predecessors, it features a patch that records the heart's electrical signals continuously for up to 14 days. Unique to the Zio AT system, however, is the inclusion of the Zio AT wireless gateway. This addition enhances connectivity between the Zio AT patch and the ZEUS System during the patient wear period, ensuring real-time data transmission and analysis. This system is also prescription-only, providing an advanced tool for healthcare providers in the management and diagnosis of cardiac conditions.

Contact Information

Address: 699 8th Street
Phone: 415 632 5700